RT Journal Article
SR Electronic
T1 Phe2vec: Automated Disease Phenotyping based on Unsupervised Embeddings from Electronic Health Records
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.14.20231894
DO 10.1101/2020.11.14.20231894
A1 Jessica K. De Freitas
A1 Kipp W. Johnson
A1 Eddye Golden
A1 Girish N. Nadkarni
A1 Joel T. Dudley
A1 Erwin P. Bottinger
A1 Benjamin S. Glicksberg
A1 Riccardo Miotto
YR 2021
UL http://medrxiv.org/content/early/2021/03/29/2020.11.14.20231894.abstract
AB Objective Robust phenotyping of patient data from electronic health records (EHRs) at scale is a current challenge in the field of clinical informatics. We introduce Phe2vec, an automated framework for disease phenotyping from EHRs based on unsupervised learning. We assess its effectiveness against standard rule-based algorithms from the Phenotype KnowledgeBase (PheKB).Materials and Methods Phe2vec is based on pre-computing embeddings of medical concepts and patients’ longitudinal clinical history. Disease phenotypes are then derived from a seed concept and its neighbors in the embedding space. Patients are similarly linked to a disease if their embedded representation is close to the phenotype. We implemented Phe2vec using 49,234 medical concepts from structured EHRs and clinical notes from 1,908,741 patients in the Mount Sinai Health System. We assessed performance on ten diverse diseases that have a PheKB algorithm.Results Phe2vec phenotypes derived using Word2vec, GloVe, and Fasttext embeddings led to promising performance in disease definition and patient cohort identification with respect to phenotypes and cohorts obtained by PheKB. When comparing Phe2vec and PheKB disease patient cohorts head-to-head using chart review, Phe2vec performed on par or better in nine out of ten diseases in terms of positive predictive values.Discussion Phe2vec offers a solution to improve time-consuming phenotyping pipelines. Differently from other approaches in the literature, it is unsupervised, can easily scale to any disease and was validated against widely adopted expert-based standards.Conclusion Phe2vec aims to optimize clinical informatics research by augmenting current frameworks to characterize patients by condition and derive reliable disease cohorts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport from the Hasso Plattner Foundation and the Alzheimer's Drug Discovery Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved under IRB-19-02369 by the Program for the Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesn/a